MA revised policies effective March 1, 2026 Bioengineered Skin and Soft Tissue Substitutes Policy number: M.3 Summary: Covers bioengineered skin substitutes for diabetic foot ulcers, venous leg ulcers, and certain reconstructive or burn indications when strict LCD criteria and approved product lists are met
2023 Alzheimers disease facts and figures
Initial evaluation of hot flashes should include thyroid function testing and, when relevant, pregnancy testing
As GLP-1s help improve mobility and reduce pain tied to conditions like osteoarthritis, they can enable more consumers to re-engage with healthier lifestyles, from exercise to more intentional nutrition
This may happen because you focus on the quick results, not on the long journey ahead to achieve long-term goals
Morning dosing is essential